未找到相关数据
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
被引：33
作者：
O'Day, S.
Hodi, F. S.
McDermott, D. F.
Weber, R. W.
Sosman, J. A.
Haanen, J. B.
Zhu, X.
Yellin, M. J.
Hoos, A.
Urba, W. J.
机构：
[1] Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] St Marys Hosp, San Francisco, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[7] Medarex Inc, Bloomsbury, NJ USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Earle A Chiles Res Inst, Portland, OR USA
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页数：1
相关论文